Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Silk sericin is a natural protein-based biologic extracted from the cocoons of the silkworm *Bombyx mori*. It is investigated primarily as a topical wound-healing agent and additive to standard antimicrobial treatments, such as silver zinc sulfadiazine (SSD) cream, for the treatment of second-degree burn wounds. Sericin promotes wound re-epithelialization and tissue repair by stimulating the migration and proliferation of fibroblasts and keratinocytes, activating collagen production, and modulating inflammatory pathways (including the downregulation of pro-inflammatory cytokines like TNF-alpha and IL-1beta). In clinical trials conducted in Thailand, the addition of silk sericin to SSD cream significantly accelerated the time to complete wound healing in patients with second-degree burns compared to SSD cream alone, without causing adverse systemic effects or infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on silk sericin.